We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
TotalEnergies
TTE
$193B
| $25.1M | 0.04% |
384,040
+48,640
| +15% | +$3.08M |
|
|
FITB
352
Fifth Third Bancorp
FITB
$51.3B
| $25.1M | 0.04% |
536,700
-5,801
| -1% | -$255K |
|
353
Dominion Energy
D
$62.1B
| $25.1M | 0.04% |
428,161
+8,680
| +2% | +$523K |
|
354
Mine Safety
MSA
$6.79B
| $25M | 0.04% |
156,202
-63,733
| -29% | -$10.4M |
|
355
Synchrony
SYF
$24.4B
| $25M | 0.04% |
299,772
-15,355
| -5% | -$1.17M |
|
356
JFrog
FROG
$8.88B
| $24.9M | 0.04% |
398,349
-211,376
| -35% | -$12M |
|
357
Pentair
PNR
$10.6B
| $24.8M | 0.04% |
238,534
-3,250
| -1% | -$347K |
|
358
Sysco
SYY
$40.8B
| $24.6M | 0.04% |
334,170
-294
| -0.1% | -$22.4K |
|
359
Biogen
BIIB
$30.9B
| $24.6M | 0.04% |
139,878
+1,013
| +0.7% | +$165K |
|
360
Steel Dynamics
STLD
$36.2B
| $24.6M | 0.04% |
145,156
+2,305
| +2% | +$366K |
|
361
Materion
MTRN
$3.94B
| $24.4M | 0.04% |
196,346
-32,007
| -14% | -$3.95M |
|
362
Vertex
VERX
$2.16B
| $24.4M | 0.04% |
1,221,776
-224,058
| -15% | -$4.85M |
|
363
Jacobs Solutions
J
$16B
| $24.2M | 0.04% |
183,038
+5,036
| +3% | +$739K |
|
364
Cboe Global Markets
CBOE
$32.2B
| $24.2M | 0.04% |
96,505
-5,274
| -5% | -$1.31M |
|
365
Kenvue
KVUE
$38B
| $24.2M | 0.04% |
1,403,475
-7,905
| -0.6% | -$129K |
|
366
D.R. Horton
DHI
$41.2B
| $24.1M | 0.04% |
167,224
-1,016
| -0.6% | -$155K |
|
367
Ulta Beauty
ULTA
$21.8B
| $24.1M | 0.04% |
39,752
-2,253
| -5% | -$1.24M |
|
368
Medpace
MEDP
$16.3B
| $24M | 0.04% |
42,748
+94
| +0.2% | +$53.4K |
|
369
Willis Towers Watson
WTW
$29.8B
| $23.9M | 0.04% |
72,707
-200
| -0.3% | -$65.5K |
|
370
Expeditors International
EXPD
$22.3B
| $23.9M | 0.04% |
160,305
+6,238
| +4% | +$849K |
|
371
EXL Service
EXLS
$5.46B
| $23.9M | 0.04% |
562,437
+89,194
| +19% | +$3.65M |
|
372
Teradyne
TER
$50B
| $23.8M | 0.04% |
123,172
+5,899
| +5% | +$1.01M |
|
373
Seacoast Banking Corp of Florida
SBCF
$3.3B
| $23.8M | 0.04% |
758,283
-45,978
| -6% | -$1.43M |
|
|
TECX
374
Tectonic Therapeutic
TECX
$536M
| $23.8M | 0.04% |
1,141,824
+785,648
| +221% | +$14.6M |
|
375
Williams-Sonoma
WSM
$27.5B
| $23.8M | 0.04% |
133,348
+11,452
| +9% | +$2.15M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.